Oxurion NV (OXUR) - Net Assets
Based on the latest financial reports, Oxurion NV (OXUR) has net assets worth €-11.99 Million EUR (≈ $-14.02 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.98 Million ≈ $5.82 Million USD) and total liabilities (€16.98 Million ≈ $19.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Oxurion NV to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-11.99 Million |
| % of Total Assets | -240.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | -144.15% |
| 10-Year Change | -106.5% |
| Growth Volatility | 48.34 |
Oxurion NV - Net Assets Trend (2006–2024)
This chart illustrates how Oxurion NV's net assets have evolved over time, based on quarterly financial data. Also explore Oxurion NV total assets for the complete picture of this company's asset base.
Annual Net Assets for Oxurion NV (2006–2024)
The table below shows the annual net assets of Oxurion NV from 2006 to 2024. For live valuation and market cap data, see Oxurion NV (OXUR) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-11.06 Million ≈ $-12.93 Million |
+16.14% |
| 2023-12-31 | €-13.19 Million ≈ $-15.42 Million |
-187.72% |
| 2022-12-31 | €-4.58 Million ≈ $-5.36 Million |
-313.63% |
| 2021-12-31 | €-1.11 Million ≈ $-1.30 Million |
-104.42% |
| 2020-12-31 | €25.05 Million ≈ $29.28 Million |
-53.01% |
| 2019-12-31 | €53.31 Million ≈ $62.32 Million |
-49.38% |
| 2018-12-31 | €105.31 Million ≈ $123.12 Million |
-21.03% |
| 2017-12-31 | €133.36 Million ≈ $155.91 Million |
+21.39% |
| 2016-12-31 | €109.86 Million ≈ $128.44 Million |
-35.38% |
| 2015-12-31 | €170.01 Million ≈ $198.77 Million |
-18.27% |
| 2014-12-31 | €208.01 Million ≈ $243.19 Million |
-19.62% |
| 2013-12-31 | €258.77 Million ≈ $302.53 Million |
+13.51% |
| 2012-12-31 | €227.97 Million ≈ $266.52 Million |
+93.14% |
| 2011-12-31 | €118.03 Million ≈ $137.99 Million |
-14.59% |
| 2010-12-31 | €138.19 Million ≈ $161.56 Million |
+47.45% |
| 2009-12-31 | €93.72 Million ≈ $109.57 Million |
+50.21% |
| 2008-12-31 | €62.39 Million ≈ $72.94 Million |
+28.82% |
| 2007-12-31 | €48.44 Million ≈ $56.63 Million |
+37.30% |
| 2006-12-31 | €35.28 Million ≈ $41.24 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oxurion NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7136400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €74.89 Million | % |
| Other Comprehensive Income | €25.25 Million | % |
| Other Components | €250.00K | % |
| Total Equity | €-11.06 Million | 100.00% |
Oxurion NV Competitors by Market Cap
The table below lists competitors of Oxurion NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Montfort Capital Corp
V:MONT
|
$313.70K |
|
Rivalry Corp
V:RVLY
|
$315.65K |
|
Exploitasi Energi Indonesia
JK:CNKO
|
$316.71K |
|
GO.D.M Investments Ltd
TA:GODM
|
$319.94K |
|
GETT Gold Inc
V:GETT
|
$309.68K |
|
IO Biotech Inc
NASDAQ:IOBT
|
$309.38K |
|
Cadence Minerals PLC
LSE:KDNC
|
$308.47K |
|
SkinBioTherapeutics PLC
LSE:SBTX
|
$307.45K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oxurion NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -13,186,000 to -11,058,000, a change of 2,128,000.
- Net income of 119,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 19,306,000.
- Other factors decreased equity by 17,297,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €119.00K | +1.08% |
| Other Comprehensive Income | €19.31 Million | +174.59% |
| Other Changes | €-17.30 Million | -156.42% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Oxurion NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | €19527.61 | €0.00 | x |
| 2007-12-31 | €20235.21 | €0.00 | x |
| 2008-12-31 | €24333.29 | €0.00 | x |
| 2009-12-31 | €35417.41 | €0.00 | x |
| 2010-12-31 | €47027.55 | €0.00 | x |
| 2011-12-31 | €36412.75 | €0.00 | x |
| 2012-12-31 | €63309.12 | €0.00 | x |
| 2013-12-31 | €70047.05 | €0.00 | x |
| 2014-12-31 | €56423.04 | €0.00 | x |
| 2015-12-31 | €46143.07 | €0.00 | x |
| 2016-12-31 | €30010.77 | €0.00 | x |
| 2017-12-31 | €36239.09 | €0.00 | x |
| 2018-12-31 | €27421.20 | €0.00 | x |
| 2019-12-31 | €13883.52 | €0.00 | x |
| 2020-12-31 | €6576.13 | €0.00 | x |
| 2021-12-31 | €-280.66 | €0.00 | x |
| 2022-12-31 | €-539.11 | €0.00 | x |
| 2023-12-31 | €-79.81 | €0.00 | x |
| 2024-12-31 | €-8.71 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oxurion NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3966.67%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-20.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -28.73% | -312.49% | 0.09x | 1.06x | €-13.66 Million |
| 2007 | -32.97% | -1275.32% | 0.02x | 1.07x | €-20.81 Million |
| 2008 | 19.39% | 39.76% | 0.45x | 1.08x | €5.86 Million |
| 2009 | -15.01% | -333.97% | 0.04x | 1.08x | €-23.44 Million |
| 2010 | -10.09% | -225.78% | 0.04x | 1.03x | €-27.76 Million |
| 2011 | -18.33% | -873.87% | 0.02x | 1.09x | €-33.44 Million |
| 2012 | 13.34% | 40.51% | 0.31x | 1.05x | €7.62 Million |
| 2013 | 10.20% | 23.41% | 0.42x | 1.05x | €523.80K |
| 2014 | -24.57% | -371.04% | 0.06x | 1.06x | €-71.92 Million |
| 2015 | -22.29% | -338.31% | 0.06x | 1.05x | €-54.88 Million |
| 2016 | -54.92% | -849.01% | 0.06x | 1.11x | €-71.30 Million |
| 2017 | 17.18% | 392.22% | 0.04x | 1.13x | €9.53 Million |
| 2018 | -36.68% | -723.20% | 0.05x | 1.10x | €-48.96 Million |
| 2019 | -97.49% | -1313.41% | 0.06x | 1.22x | €-57.14 Million |
| 2020 | -111.25% | -1348.03% | 0.06x | 1.36x | €-30.53 Million |
| 2021 | 0.00% | -2584.93% | 0.06x | 0.00x | €-29.05 Million |
| 2022 | 0.00% | -5325.21% | 0.05x | 0.00x | €-31.23 Million |
| 2023 | 0.00% | -7212.55% | 0.04x | 0.00x | €-17.65 Million |
| 2024 | 0.00% | 3966.67% | 0.00x | 0.00x | €1.22 Million |
Industry Comparison
This section compares Oxurion NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,685,203,849
- Average return on equity (ROE) among peers: -42.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oxurion NV (OXUR) | €-11.99 Million | -28.73% | N/A | $311.42K |
| Argen-X (ARGX) | $413.81 Million | -8.14% | 0.08x | $42.08 Billion |
| BioSenic S.A. (BIOS) | $-9.48 Million | 0.00% | 0.00x | $1.57 Million |
| Celyad SA (CYAD) | $8.69 Million | -77.22% | 1.01x | $8.95 Million |
| Hyloris Developmentsen Sa (HYL) | $55.05 Million | -21.63% | 0.12x | $168.91 Million |
| Onward Medical N.V. (ONWD) | $17.93 Million | -201.78% | 1.43x | $184.65 Million |
| Tubize-Fin (TUB) | $443.43 Million | 0.00% | 0.18x | $9.89 Billion |
| UCB SA (UCB) | $10.87 Billion | 14.34% | 0.67x | $51.74 Billion |
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more